WBRT & Erlotinib in Advanced NSCLC and Brain Metastases

Summary

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Erlotinib may also make tumor cells more sensitive to radiation therapy. It is not yet known whether giving whole-brain radiation therapy together with erlotinib is more effective than whole-brain radiation therapy alone in treating patients with non-small cell lung cancer and brain metastases. PURPOSE: This randomized phase II trial is studying whole-brain radiation therapy and erlotinib to see how well they work compared with whole-brain radiation therapy alone in treating patients with advanced non-small cell lung cancer and brain metastases.

Timeline

Start

2008-01

Primary completion

2010-11

Completion

2010-11

Outcome

Outcome not reported

Stopped: “IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was not met.”

Drugs

Indications